S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:GMAB

Genmab A/S (GMAB) Stock Price, News & Analysis

$29.91
-0.72 (-2.35%)
(As of 03/28/2024 ET)
Today's Range
$29.84
$30.56
50-Day Range
$26.43
$31.68
52-Week Range
$26.32
$42.99
Volume
361,389 shs
Average Volume
642,308 shs
Market Capitalization
$19.76 billion
P/E Ratio
31.16
Dividend Yield
N/A
Price Target
$48.50

Genmab A/S MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
62.2% Upside
$48.50 Price Target
Short Interest
Healthy
0.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Genmab A/S in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
36.70%
From $1.09 to $1.49 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.84 out of 5 stars

Medical Sector

249th out of 938 stocks

Biotechnology Industry

6th out of 30 stocks

GMAB stock logo

About Genmab A/S Stock (NASDAQ:GMAB)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

GMAB Stock Price History

GMAB Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Transactions in Connection with Share Buy-back Program
Genmab A/S ADR
The 10 best dressed from the 2024 NAACP Image Awards
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Completion of share buy-back program
GMAB Apr 2024 30.000 put
Genmab To Repurchase Up To DKK 3.5 Bln Of Shares
Genmab Announces Initiation of Share Buy-Back Program
Transactions in connection with share buy-back program
Truist Financial Reaffirms Their Buy Rating on Genmab (GMAB)
Genmab's SBLA For Epcoritamab-bysp Granted Priority Review By FDA
See More Headlines
Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:GMAB
Fax
N/A
Employees
2,204
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$48.50
High Stock Price Target
$50.00
Low Stock Price Target
$46.00
Potential Upside/Downside
+62.2%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$631.91 million
Pretax Margin
34.22%

Debt

Sales & Book Value

Annual Sales
$2.39 billion
Cash Flow
$1.20 per share
Book Value
$6.95 per share

Miscellaneous

Free Float
650,570,000
Market Cap
$19.76 billion
Optionable
Optionable
Beta
0.98

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Jan G.J. van de Winkel Ph.D. (Age 63)
    Co-Founder, President & CEO
    Comp: $2.9M
  • Mr. Anthony Pagano (Age 46)
    Executive VP & CFO
    Comp: $1.03M
  • Ms. Birgitte Stephensen M.Sc. (Age 63)
    Executive VP & Chief Legal Officer
    Comp: $638.88k
  • Dr. Martine J. van Vugt Ph.D. (Age 53)
    Executive VP & Chief Strategy Officer
    Comp: $696.97k
  • Mr. Martin Schultz (Age 48)
    Senior Director of Clinical Operations & Non-Independent Director
    Comp: $116.16k
  • Dr. Tahamtan Ahmadi (Age 51)
    Executive VP, Chief Medical Officer & Head of Experimental Medicines
    Comp: $1.12M
  • Dr. Mijke Zachariasse Ph.D. (Age 50)
    Senior Director, Head of Antibody Research Materials & Non-Independent Director
    Comp: $159.72k
  • Mr. Takahiro Hamatani (Age 49)
    Senior Director of Finance Japan & Non-Independent Director
    Comp: $116.16k
  • Mr. Anthony Mancini (Age 53)
    Executive VP & COO
    Comp: $1.1M
  • Mr. Andrew Carlsen
    Senior Director, VP & Head of Investor Relations

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Genmab A/S was last updated on Tuesday, March 26, 2024 at 11:05 PM.

Pros

Here are some ways that investors could benefit from investing in Genmab A/S:

  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases, showing a commitment to addressing critical medical needs.
  • The company has a diverse product portfolio including DARZALEX, teprotumumab, and Amivantamab, targeting various types of cancer, which can potentially lead to revenue growth.
  • Genmab A/S has collaborations with reputable companies like Seagen Inc., argenx, and AbbVie, enhancing its research and development capabilities and market reach.
  • Recent developments indicate positive market sentiment towards Genmab A/S, with an average target price of $48.50, suggesting potential for stock price appreciation.
  • The company is actively involved in pre-clinical programs, indicating a focus on innovation and future growth opportunities in the pharmaceutical industry.

Cons

Investors should be bearish about investing in Genmab A/S for these reasons:

  • Genmab A/S operates in a highly competitive pharmaceutical industry, facing challenges such as regulatory hurdles, market competition, and potential patent expirations.
  • The success of Genmab A/S heavily relies on the performance of its key products like DARZALEX and Amivantamab, making the company vulnerable to any setbacks in these products' development or commercialization.
  • Investing in biopharmaceutical companies like Genmab A/S involves inherent risks related to clinical trial outcomes, regulatory approvals, and market acceptance of new treatments.
  • Fluctuations in the healthcare sector, changes in healthcare policies, and unexpected events like pandemics can impact the financial performance and stock price of Genmab A/S.
  • Investors should consider the potential impact of macroeconomic factors, currency fluctuations, and global market conditions on Genmab A/S's operations and financial results.

GMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Genmab A/S stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 3 sell ratings, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View GMAB analyst ratings
or view top-rated stocks.

What is Genmab A/S's stock price target for 2024?

13 Wall Street analysts have issued 12-month price targets for Genmab A/S's stock. Their GMAB share price targets range from $46.00 to $50.00. On average, they predict the company's stock price to reach $48.50 in the next twelve months. This suggests a possible upside of 62.2% from the stock's current price.
View analysts price targets for GMAB
or view top-rated stocks among Wall Street analysts.

How have GMAB shares performed in 2024?

Genmab A/S's stock was trading at $31.84 on January 1st, 2024. Since then, GMAB shares have decreased by 6.1% and is now trading at $29.91.
View the best growth stocks for 2024 here
.

Are investors shorting Genmab A/S?

Genmab A/S saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,050,000 shares, an increase of 10.2% from the February 29th total of 1,860,000 shares. Based on an average daily trading volume, of 623,600 shares, the short-interest ratio is currently 3.3 days. Currently, 0.3% of the shares of the stock are short sold.
View Genmab A/S's Short Interest
.

When is Genmab A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our GMAB earnings forecast
.

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) announced its quarterly earnings results on Wednesday, February, 14th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.02. The company earned $675.29 million during the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a trailing twelve-month return on equity of 18.06% and a net margin of 26.50%.

What guidance has Genmab A/S issued on next quarter's earnings?

Genmab A/S updated its FY 2024 earnings guidance on Wednesday, February, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.7 billion-$3.0 billion, compared to the consensus revenue estimate of $2.8 billion.

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).

When did Genmab A/S IPO?

Genmab A/S (GMAB) raised $503 million in an IPO on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by many different retail and institutional investors. Top institutional shareholders include Capital International Investors (0.61%), Harding Loevner LP (0.50%), Wellington Management Group LLP (0.36%), First Trust Advisors LP (0.19%), Envestnet Asset Management Inc. (0.14%) and Stifel Financial Corp (0.10%).

How do I buy shares of Genmab A/S?

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GMAB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners